摘要
肾性贫血是慢性肾脏病(CKD)常见并发症之一,对患者的预后影响深远。传统的肾性贫血治疗方式,如促红细胞生成素和铁剂,对部分患者疗效不甚理想,且可能伴随不良反应,迫切需要寻找新的治疗方案。近期研究揭示,膜铁转运蛋白1(FPN1)在肾性贫血进展中起着关键的作用。本文将对FPN1在肾性贫血铁代谢中的调控机制,以及针对FPN1的治疗策略在肾性贫血治疗进展中的作用作一简述。
Renal anemia is one of the common complications of chronic kidney disease(CKD),which has a profound impact on the prognosis of patients.The traditional treatment of renal anemia,such as the use of erythropoietin(EPO)and iron,is not ideal for some patients,and may be accompanied by adverse reactions.Therefore,there is an urgent need to find new treatment options.Recent studies have revealed that ferroportin 1(FPN1)plays a key role in the treatment of renal anemia.In this review,the regulatory mechanism of FPN1 in iron metabolism in renal anemia and the role of treatment strategies targeting FPN1 in the progress of renal anemia treatment are discussed in detail.
作者
曹媛
李洋(综述)
王尊松(审校)
CAO Yuan;LI Yang;WANG Zunsong(Department of Nephrology,The First Affiliated Hospital of Shandong First Medical University&Shandong Provincial Qianfoshan Hospital,Shandong Institute of Nephrology,Jinan 250014,China)
出处
《肾脏病与透析肾移植杂志》
2025年第4期376-380,390,共6页
Chinese Journal of Nephrology,Dialysis & Transplantation
基金
山东省自然科学基金(ZR2023MH255)。
